A support 70 for use with tissue or bone is described, the support 70 having one or more spaced apart brace members 72, and at least one elongated linking member 80 for linking to the one or more spaced apart brace members 72. The support 70 may be provided in use in combination with a biologic glue, the biologic glue comprising a first portion containing stabilized blood product, and a second portion containing a growth factor, the first portion and the second portion comingled when or after the support is introduced to the tissue or bone in a subject in need thereof. The support 70 is fabricated by actively producing the support through an additive manufacturing process, in which the support 70 is customized specifically to the tissue or bone by creating a computer generated construct of the support 70 on a three-dimensional volume rendering of the tissue or bone, and the computer generated construct is interpretable via software directing the additive manufacturing process.

Compositions and surgical methods are provided for repairing damaged avascular zones, including intervertebral disc, in a patient in need thereof.

In vitro and in vivo application of sub-atmospheric, negative pressure on growth factor starting material, such as whole blood, extracts growth factors from the platelet granules of the growth factor starting material in a non-destructive medium without activating the clotting process. The extracted growth factors are released into a growth factor composition containing blood plasma, extracellular fluid or interstitial fluid depending upon the type and location of the growth factor starting material. The growth factors have a weight of about 70-76 kDaltons and are applied in either a filtered or unfiltered state topically to the area of a surface wound to effect healing. The extracted growth factors are also injected into soft tissue, such as a torn tendon, to promote tissue growth and healing. The growth factors are released in one method from a patient's own blood. In another method the growth factors are released from a whole blood source and freeze dried by lyophilization. Then at a later date, the freeze-dried product is reconstituted by normal saline for treatment of a patient's wound, for use in a surgical procedure, or for tissue regeneration.

A device for mixing a bone material with a liquid is provided. The device comprises a chamber having a proximal end and a distal end, and the bone material disposed within the chamber, the bone material comprising a DBM pellet of milled and lyophilized demineralized bone fibers; and a plunger having at least a portion slidably disposed within the proximal end of the chamber and configured to dispense the bone material mixed with liquid from the distal end of the chamber, when the plunger is in an extended position.

The present invention concerns a cell-enriched fat graft and methods of making and using the same. The present invention also provides a kit for making and using the cell-enriched fat graft of invention.

The present disclosure features adhesive compositions and methods of use thereof related to the medical, veterinary, and dental fields.

The disclosure provides a method of using blood or fractions thereof, e.g., serum, obtained from a mammal subjected to liver surgery, for example, obtained following a partial hepatectomy, to increase the engraftment, proliferation and/or functionality of cells on a biocompatible scaffold.

Cancellous bone material may be processed in a portable container apparatus to prepare a stromal vascular fraction concentrate. Cancellous bone material may be washed to remove non-bone material, digested and digested material centrifuged, with all operations being performed on cancellous bone material while disposed in the portable container apparatus. Uncultured stromal vascular fraction cells separated from enzyme-digested cancellous bone material, and which contain osteoblasts and osteoclasts, may be removed from the portable container and used without culturing for a variety of medical applications. Medical treatment compositions may be prepared including recovered stromal vascular fraction cells and scaffold material.

The present invention relates to methods for recellurization of blood vessels. This method is particularly useful for producing an allogeneic vein, wherein a donor vein is decellularized and then recellularized using whole blood or bone marrow stem cells. The allogeneic veins produced by the methods disclosed herein are particularly advantageous for implantation or transplantation into patients with vascular diseases.

The described invention provides a method of functionally reprogramming adult cells to an immature cell type that expresses one or more embryonic biomarkers. The reprogramming is accomplished by contacting the adult cells with a platelet rich fraction comprising platelet-like cells from umbilical cord blood or peripheral blood, and expanding the immature cell type in vitro under culture conditions to generate an insulin-producing cell population that expresses human beta-cell specific transcription factors and is functionally equivalent to human pancreatic beta-cells. Without being limited by theory, platelet-like cells and their released mitochondria display immune tolerance-associated markers that may modulate the function and differentiation of immune cells. The described invention further provides a pharmaceutical composition comprising a cell product containing a therapeutic amount of an insulin-producing cell population derived from functionally reprogrammed adult cells, wherein the insulin-producing cell population expresses human beta-cell specific transcription factors and is functionally equivalent to human pancreatic beta-cells.